A Block-randomized, Double-blind, Placebo-controlled, Single-dose, Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers

NCT02097043 Phase 1 COMPLETED

This study is a phase I clinical trial for evaluating the pharmacokinetics and safety/tolerability of DA-7218 in healthy male volunteers.

Details

Lead sponsor	Dong-A ST Co., Ltd.
Phase	Phase 1
Status	COMPLETED
Enrolment	31
Start date	2014-05
Completion	2014-05

Conditions

• Healthy

Interventions

• DA-7218
• Placebo

Primary outcomes

• AUClast — 72 hours
  Area under the concentration-time curve from time zero to the last quantifiable concentration by linear trapezoidal method
• Cmax — 72 hours

Countries

South Korea